

Anti Obesity Drugs-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/A8B977BCE87MEN.html>

Date: February 2018

Pages: 143

Price: US\$ 3,480.00 (Single User License)

ID: A8B977BCE87MEN

Abstracts

Report Summary

Anti Obesity Drugs-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Anti Obesity Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Anti Obesity Drugs 2013-2017, and development forecast 2018-2023

Main market players of Anti Obesity Drugs in EMEA, with company and product introduction, position in the Anti Obesity Drugs market

Market status and development trend of Anti Obesity Drugs by types and applications

Cost and profit status of Anti Obesity Drugs, and marketing status

Market growth drivers and challenges

The report segments the EMEA Anti Obesity Drugs market as:

EMEA Anti Obesity Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Anti Obesity Drugs Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oral Medicine

Diet Patch

Diet Tea

EMEA Anti Obesity Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Men

Women

EMEA Anti Obesity Drugs Market: Players Segment Analysis (Company and Product introduction, Anti Obesity Drugs Sales Volume, Revenue, Price and Gross Margin):

Pfizer

Merck

Roche

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Novo Nordisk

Eisai

Norgine

Arena Pharmaceuticals

Orexigen Therapeutics

Vivus

Alizyme

Rhythm Pharmaceuticals

Shionogi

Zafgan

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF ANTI OBESITY DRUGS

- 1.1 Definition of Anti Obesity Drugs in This Report
- 1.2 Commercial Types of Anti Obesity Drugs
 - 1.2.1 Oral Medicine
 - 1.2.2 Diet Patch
 - 1.2.3 Diet Tea
- 1.3 Downstream Application of Anti Obesity Drugs
 - 1.3.1 Men
 - 1.3.2 Women
- 1.4 Development History of Anti Obesity Drugs
- 1.5 Market Status and Trend of Anti Obesity Drugs 2013-2023
 - 1.5.1 EMEA Anti Obesity Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Anti Obesity Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Anti Obesity Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Anti Obesity Drugs in EMEA by Regions
 - 2.2.1 Consumption Volume of Anti Obesity Drugs in EMEA by Regions
 - 2.2.2 Revenue of Anti Obesity Drugs in EMEA by Regions
- 2.3 Market Analysis of Anti Obesity Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Anti Obesity Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Anti Obesity Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Anti Obesity Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Anti Obesity Drugs in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Anti Obesity Drugs in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Anti Obesity Drugs by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Anti Obesity Drugs in EMEA by Types
 - 3.1.2 Revenue of Anti Obesity Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East

- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Anti Obesity Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Anti Obesity Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Anti Obesity Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Anti Obesity Drugs by Downstream Industry in Europe
 - 4.2.2 Demand Volume of Anti Obesity Drugs by Downstream Industry in Middle East
 - 4.2.3 Demand Volume of Anti Obesity Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Anti Obesity Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ANTI OBESITY DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Anti Obesity Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 ANTI OBESITY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Anti Obesity Drugs in EMEA by Major Players
- 6.2 Revenue of Anti Obesity Drugs in EMEA by Major Players
- 6.3 Basic Information of Anti Obesity Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Anti Obesity Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Anti Obesity Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 ANTI OBESITY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Pfizer
 - 7.1.1 Company profile
 - 7.1.2 Representative Anti Obesity Drugs Product
 - 7.1.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Pfizer

7.2 Merck

7.2.1 Company profile

7.2.2 Representative Anti Obesity Drugs Product

7.2.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Merck

7.3 Roche

7.3.1 Company profile

7.3.2 Representative Anti Obesity Drugs Product

7.3.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Roche

7.4 GlaxoSmithKline

7.4.1 Company profile

7.4.2 Representative Anti Obesity Drugs Product

7.4.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline

7.5 AstraZeneca

7.5.1 Company profile

7.5.2 Representative Anti Obesity Drugs Product

7.5.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca

7.6 Boehringer Ingelheim

7.6.1 Company profile

7.6.2 Representative Anti Obesity Drugs Product

7.6.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Boehringer

Ingelheim

7.7 Novo Nordisk

7.7.1 Company profile

7.7.2 Representative Anti Obesity Drugs Product

7.7.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk

7.8 Eisai

7.8.1 Company profile

7.8.2 Representative Anti Obesity Drugs Product

7.8.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Eisai

7.9 Norgine

7.9.1 Company profile

7.9.2 Representative Anti Obesity Drugs Product

7.9.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Norgine

7.10 Arena Pharmaceuticals

7.10.1 Company profile

7.10.2 Representative Anti Obesity Drugs Product

7.10.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Arena

Pharmaceuticals

7.11 Orexigen Therapeutics

- 7.11.1 Company profile
- 7.11.2 Representative Anti Obesity Drugs Product
- 7.11.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
- 7.12 Vivus
 - 7.12.1 Company profile
 - 7.12.2 Representative Anti Obesity Drugs Product
 - 7.12.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Vivus
- 7.13 Alizyme
 - 7.13.1 Company profile
 - 7.13.2 Representative Anti Obesity Drugs Product
 - 7.13.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Alizyme
- 7.14 Rhythm Pharmaceuticals
 - 7.14.1 Company profile
 - 7.14.2 Representative Anti Obesity Drugs Product
 - 7.14.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Rhythm Pharmaceuticals
- 7.15 Shionogi
 - 7.15.1 Company profile
 - 7.15.2 Representative Anti Obesity Drugs Product
 - 7.15.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Shionogi
- 7.16 Zafgan

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI OBESITY DRUGS

- 8.1 Industry Chain of Anti Obesity Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ANTI OBESITY DRUGS

- 9.1 Cost Structure Analysis of Anti Obesity Drugs
- 9.2 Raw Materials Cost Analysis of Anti Obesity Drugs
- 9.3 Labor Cost Analysis of Anti Obesity Drugs
- 9.4 Manufacturing Expenses Analysis of Anti Obesity Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF ANTI OBESITY DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Anti Obesity Drugs-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/A8B977BCE87MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A8B977BCE87MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970